This site is intended for health professionals only
Friday 24 May 2019
Share |

Topic: Conference reports

December 1, 2017
More than 3500 people attended the European Association of Hospital Pharmacists Congress in Cannes in March. Key topics included affordability of medicines, big data, evidence-based anticoagulation and the current status of biosimilars
There is a widespread public perception that prices for medicines are unfair, according to Suzannne Hill (Department of essential medicines and health products, World Health Organization (WHO)). “It is now important to consider how we should pay for new medicines, what we can afford, and how to make the system sustainable”, she continued.
 
December 1, 2017
Biosimilar medicines offer great potential for increasing access to biologics. Here, we report on a multidisciplinary debate around biosimilars, supported by Sandoz, that took place at the 22nd EAHP congress in Cannes on 22 March 2017

Support for the editorial  development of this report was provided by Sandoz

 

Alain Astier

Alain Astier Professor of Oncology Pharmacy and Biotechnics, Henri Mondor University Hospital, Paris, France

 

Arnold Vulto

December 1, 2017
To compound, or not to compound, that is not the question: Whether it is preferable to use standardised multi-chamber bags, to keep the compounding in house, or to outsource it, should be decided by every hospital, being a unique case that requires a custom-fit approach

Support for the development of this editorial report was provided by the Business Unit Compounding of Fresenius Kabi

 

 

November 30, 2017
At their annual Conference on 25 November 2017 the UKCPA celebrated two outstanding leaders in pharmacy

Mr Philip Howard, Consultant Pharmacist in Antimicrobials at Leeds Teaching Hospitals NHS Trust, was given the UKCPA Lifetime Achievement Award for 2017.
 

May 18, 2015
A new awards programme, Bayer Ophthalmology Honours, has been launched by Bayer HealthCare at the Royal College of Ophthalmologists’ Annual Congress. The programme aims to recognise and celebrate, on an annual basis, the outstanding work being carried out by multi-disciplinary teams in ophthalmology throughout the UK. Supported by the Macular Society and the Royal National Institute of Blind People (RNIB), the awards will identify exceptional initiatives that demonstrate clinical excellence and innovation in ophthalmology.

A new awards programme, Bayer Ophthalmology Honours, has been launched by Bayer HealthCare at the Royal College of Ophthalmologists’ Annual Congress. The programme aims to recognise and celebrate, on an annual basis, the outstanding work being carried out by multi-disciplinary teams in ophthalmology throughout the UK. Supported by the Macular Society and the Royal National Institute of Blind People (RNIB), the awards will identify exceptional initiatives that demonstrate clinical excellence and innovation in ophthalmology.
 

April 29, 2015
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
 
Ursula Theuretzbacher, the founder of the Centre for Anti-Infective Agents in Vienna, led the session, which gave a review of the research and development programmes from across some of the most innovative and nimble European biotech companies.

March 11, 2015
New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.

New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.
 

 

February 20, 2015
Celltrion Healthcare has announced data demonstrating that the world’s first biosimilar monoclonal antibody (mAb) infliximab is an effective treatment option for patients with the chronic debilitating autoimmune diseases, Crohn’s disease (CD) and ulcerative colitis (UC). Clinical experience of biosimilar infliximab in 332 patients with inflammatory bowel disease (IBD) is being presented in six posters and a satellite symposium at ECCO 2015 showing that the treatment is effective and safe in these patients.

Celltrion Healthcare has announced data demonstrating that the world’s first biosimilar monoclonal antibody (mAb) infliximab is an effective treatment option for patients with the chronic debilitating autoimmune diseases, Crohn’s disease (CD) and ulcerative colitis (UC). Clinical experience of biosimilar infliximab in 332 patients with inflammatory bowel disease (IBD) is being presented in six posters and a satellite symposium at ECCO 2015 showing that the treatment is effective and safe in these patients.

 

 

November 17, 2014
A new report on medicines shortages experienced in European healthcare systems reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines with 66% reporting this as a daily or weekly problem. The top affected areas are medicines to fight infection, cancer drugs and anaesthetics.

A new report on medicines shortages experienced in European healthcare systems reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines with 66% reporting this as a daily or weekly problem. The top affected areas are medicines to fight infection, cancer drugs and anaesthetics.
 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine